MedPath

Chemotherapy Followed by Surgery and Neoadjuvant Hemothoracic Intensity Modified Radiation Therapy (IMRT) for Patients With Malignant Pleural Mesothelioma

Terminated
Conditions
Mesothelioma
Solitary Fibrous Tumor of the Pleura
Registration Number
NCT02613312
Lead Sponsor
Mayo Clinic
Brief Summary

The purpose of this study is to determine the response rate and overall survival in patients that have been diagnosed with mesothelioma and will undergo chemotherapy, surgery and intensity modified radiation therapy (IMRT) as part of their standard of care.

Detailed Description

The investigators will consent patients that have been diagnosed with mesothelioma and will undergo chemotherapy followed by surgery and then IMRT as their standard of care. The investigators will collect data from past and future medical records as well as data regarding their health status for their lifetime by reviewing life status, treatment status and CT scans.

Recruitment & Eligibility

Status
TERMINATED
Sex
All
Target Recruitment
8
Inclusion Criteria
  • Subject provides informed consent
  • Subject is >18 years of age
  • Subject is deemed competent for making medical decisions
  • Subject is scheduled to undergo chemotherapy followed by surgery and then IMRT
  • Subject is a surgical candidate
  • A negative pregnancy test is required in women of child-bearing potential, as standard of care.
Exclusion Criteria

•Subject is <18 years old.

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Overall Survival (OS)2 years

OS is defined as the length of time from study enrollment to death by any cause. Survival status of patients will be monitored every 6 months

Secondary Outcome Measures
NameTimeMethod
Progression free survival (PFS) as evidenced by CT scan review2 years

PFS is defined as the length of time from study enrollment to the time of disease progression.

Trial Locations

Locations (1)

Mayo Clinic in Rochester

🇺🇸

Rochester, Minnesota, United States

© Copyright 2025. All Rights Reserved by MedPath